Coherus BioSciences (NASDAQ:CHRS - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $7.00 price objective on the biotechnology company's stock.
Separately, Robert W. Baird raised their target price on Coherus BioSciences from $4.00 to $6.00 and gave the company an "outperform" rating in a research note on Thursday, December 5th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $5.38.
Get Our Latest Analysis on Coherus BioSciences
Coherus BioSciences Stock Performance
CHRS opened at $1.04 on Tuesday. Coherus BioSciences has a twelve month low of $0.66 and a twelve month high of $2.64. The firm has a market cap of $120.53 million, a price-to-earnings ratio of -13.00 and a beta of 0.92. The company has a fifty day simple moving average of $1.25 and a 200 day simple moving average of $1.19.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in CHRS. Bank of Montreal Can bought a new position in Coherus BioSciences during the fourth quarter worth $34,000. Steph & Co. acquired a new stake in shares of Coherus BioSciences during the fourth quarter worth $34,000. Systematic Financial Management LP bought a new position in shares of Coherus BioSciences in the 3rd quarter worth about $28,000. Intech Investment Management LLC acquired a new position in shares of Coherus BioSciences in the 4th quarter valued at about $38,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Coherus BioSciences during the 4th quarter valued at about $52,000. Institutional investors and hedge funds own 72.82% of the company's stock.
Coherus BioSciences Company Profile
(
Get Free Report)
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Coherus BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coherus BioSciences wasn't on the list.
While Coherus BioSciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
